Amp Ltd. Stock
Price
Target price
?
?
1.560%
0.02
1.560%
-
08:32 / Stuttgart Stock Exchange
WKN: 914928 / Symbol: AMLTF / Name: AMP / Stock / Investment Banking & Investment Services / Large Cap /
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.
Your prediction
Amp Ltd. Stock
There is an upward development for Amp Ltd. compared to yesterday, with an increase of €0.020 (1.560%).
Pros and Cons of Amp Ltd. in the next few years
Pros
?
G***** c******* t* c**********
?
B****
?
S********** s********
Cons
?
M***** P*******
?
C******** o* t** e**********
?
W********* I********* f** t** n*** y****
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Amp Ltd. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Amp Ltd. | 1.560% | 1.600% | 38.043% | 45.143% | 23.301% | 88.148% | 93.893% |
| National Australia Bank | 1.280% | 3.295% | 10.533% | 19.485% | 5.622% | 46.290% | 55.121% |
| Commonwealth Bank Australia | 1.760% | 2.665% | 8.609% | 12.214% | 17.597% | 65.303% | 72.908% |
| Macquarie Group Ltd | 1.680% | 1.224% | 3.848% | 31.580% | 35.344% | 45.444% | 59.036% |
News
Ardagh Metal Packaging Q2 Earnings Call Highlights
Key Points
- Interested in Ardagh Metal Packaging S.A.? Here are five stocks we like better.
- Ardagh Metal Packaging raised full-year 2026 adjusted EBITDA guidance to $775 million-$790 million
Amphastar Pharmaceuticals Pivots to Proprietary Drugs, Biosimilars for Growth
Key Points
- Interested in Amphastar Pharmaceuticals, Inc.? Here are five stocks we like better.
- Amphastar is shifting its strategy from complex generics toward proprietary drugs and
Pennon Group H2 Earnings Call Highlights
Key Points
- Interested in Pennon Group Plc? Here are five stocks we like better.
- Pennon returned to profitability in 2025/2026, with EBITDA up 55% and underlying operating profit more than